Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug to reverse breast cancer spread in development

27.01.2014
Compound trialed on mice showed a complete halt in spread of metastatic tumors

Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

The vast majority of deaths from cancer result from its progressive spread to vital organs, known as metastasis. In breast cancer up to 12,000 patients a year develop this form of the disease, often several years after initial diagnosis of a breast lump.

In a recent series of studies researchers identified a previously unknown critical role for a potential cancer causing gene, Bcl3, in metastatic breast cancer.

"We showed that suppressing this gene reduced the spread of cancer by more than 80%," said Dr Richard Clarkson from Cardiff University's European Cancer Stem Cell Research Institute.

"Our next goal was to then find a way to suppress Bcl3 pharmacologically. Despite great improvements in therapy of early stage breast cancer, the current therapeutic options for patients with late stage metastatic disease are limited.

"There is therefore a clear unmet clinical need to identify new drugs to reverse or at least to slow down disease progression" he added.

Dr Clarkson and his team joined up with researchers Dr Andrea Brancale and Dr Andrew Westwell from the Cardiff University School of Pharmacy and Pharmaceutical Sciences, to develop small chemical inhibitors of the Bcl3 gene.

Computer aided modeling of how the Bcl3 gene functions inside the cell allowed the group to identify a pocket on the surface of Bcl3 essential for its function. By screening a virtual compound library for chemicals that could fit inside this pocket, using state-of-the-art computer software, they identified a drug candidate that potently inhibits Bcl3.

The compound was then trialed on mice with metastatic disease. The resulting effect was that the drug completely inhibited the development of the mice's metastatic tumours.

With financial backing from Tiziana Pharmaceuticals*, work is now underway to progress the compound to clinical trials. The aim is to develop a therapeutic agent capable of blocking metastatic disease in breast cancer and a variety of tumour types.

Tomas Llewelyn Barrett | EurekAlert!
Further information:
http://www.cardiff.ac.uk

More articles from Life Sciences:

nachricht Genetic Regulation of the Thymus Function Identified
23.08.2016 | Universität Basel

nachricht Sun protection for plants - Plant substances can protect plants against harmful UV radiation
22.08.2016 | Max-Planck-Institut für Molekulare Pflanzenphysiologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: X-ray optics on a chip

Waveguides are widely used for filtering, confining, guiding, coupling or splitting beams of visible light. However, creating waveguides that could do the same for X-rays has posed tremendous challenges in fabrication, so they are still only in an early stage of development.

In the latest issue of Acta Crystallographica Section A: Foundations and Advances , Sarah Hoffmann-Urlaub and Tim Salditt report the fabrication and testing of...

Im Focus: Piggyback battery for microchips: TU Graz researchers develop new battery concept

Electrochemists at TU Graz have managed to use monocrystalline semiconductor silicon as an active storage electrode in lithium batteries. This enables an integrated power supply to be made for microchips with a rechargeable battery.

Small electrical gadgets, such as mobile phones, tablets or notebooks, are indispensable accompaniments of everyday life. Integrated circuits in the interiors...

Im Focus: UCI physicists confirm possible discovery of fifth force of nature

Light particle could be key to understanding dark matter in universe

Recent findings indicating the possible discovery of a previously unknown subatomic particle may be evidence of a fifth fundamental force of nature, according...

Im Focus: Wi-fi from lasers

White light from lasers demonstrates data speeds of up to 2 GB/s

A nanocrystalline material that rapidly makes white light out of blue light has been developed by KAUST researchers.

Im Focus: Every atom counts

Malignant cancer cells not only proliferate faster than most body cells. They are also more dependent on the most important cellular garbage disposal unit, the proteasome, which degrades defective proteins. Therapies for some types of cancer exploit this dependence: Patients are treated with inhibitors, which block the proteasome. The ensuing pile-up of junk overwhelms the cancer cell, ultimately killing it. Scientists have now succeeded in determining the human proteasome’s 3D structure in unprecedented detail and have deciphered the mechanism by which inhibitors block the proteasome. Their results will pave the way to develop more effective proteasome inhibitors for cancer therapy.

In order to understand how cellular machines such as the proteasome work, it is essential to determine their three-dimensional structure in detail. With its...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

A week of excellence: 22 of the world’s best computer scientists and mathematicians in Heidelberg

12.08.2016 | Event News

Towards the connected, automated and electrified automobiles: AMAA conference in Brussels

02.08.2016 | Event News

Clash of Realities 2016: 7th Conference on the Art, Technology and Theory of Digital Games

29.07.2016 | Event News

 
Latest News

New microchip demonstrates efficiency and scalable design

23.08.2016 | Information Technology

Genetic Regulation of the Thymus Function Identified

23.08.2016 | Life Sciences

Biomass turnover time in ecosystems is halved by land use

23.08.2016 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>